Enfuvirtide
Alternative Names: DP 178; Fuzeon; Pentafuside; R-698; T-20Latest Information Update: 29 Jul 2021
Price :
$50 *
At a glance
- Originator Duke University; Trimeris
- Developer Alexion AstraZeneca Rare Disease; Trimeris
- Class Antiretrovirals; Antivirals; Env gene products; Peptide fragments; Viral fusion proteins
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 23 Jun 2015 Synageva BioPharma has been acquired by Alexion Pharmaceuticals
- 02 Nov 2011 Trimeris has merged with Synageva BioPharma